RT Journal Article
SR Electronic
T1 A case series of SARS-CoV-2 reinfections caused by the variant of concern Gamma in Brazil
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.29.21266109
DO 10.1101/2021.11.29.21266109
A1 Naveca, Felipe Gomes
A1 Nascimento, Valdinete Alves
A1 Nascimento, Fernanda
A1 Ogrzewalska, Maria
A1 Pauvolid-Corrêa, Alex
A1 Araujo, Mia Ferreira
A1 Arantes, Ighor
A1 Rocha Batista, Érika Lopes
A1 Álvares Magalhães, Alessandro Leonardo
A1 Vinhal, Fernando
A1 Mattos, Tirza Peixoto
A1 Riediger, Irina
A1 Carmo Debur, Maria do
A1 Grinsztejn, Beatriz
A1 Veloso, Valdiléa G
A1 Brasil, Patricia
A1 Rodrigues, Rodrigo Ribeiro
A1 Rovaris, Darcita Buerger
A1 Fernandes, Sandra Bianchini
A1 Fernandes, Cristiano
A1 Abdalla Santos, João Hugo
A1 Abdalla, Lígia Fernandes
A1 Costa-Filho, Rubens
A1 Silva, Marineide
A1 Souza, Victor
A1 Costa, Ágatha Araújo
A1 Mejía, Matilde
A1 Brandão, Maria Júlia
A1 Gonçalves, Luciana Fé
A1 Silva, George Allan
A1 de Jesus, Michele Silva
A1 Pessoa, Karina
A1 Guerra Corado, André de Lima
A1 Gomes Duarte, Debora Camila
A1 Machado, Ana Beatriz
A1 de Azevedo Zukeram, Ketiuce
A1 Valente, Natalia
A1 Lopes, Renata Serrano
A1 Pereira, Elisa Cavalcante
A1 Appolinario, Luciana Reis
A1 Rocha, Alice Sampaio
A1 Lopez Tort, Luis Fernando
A1 Sekizuka, Tsuyoshi
A1 Itokawa, Kentaro
A1 Hashino, Masanori
A1 Kuroda, Makoto
A1 Wallau, Gabriel Luz
A1 Delatorre, Edson
A1 Gräf, Tiago
A1 Siqueira, Marilda Mendonça
A1 Bello, Gonzalo
A1 Resende, Paola Cristina
YR 2021
UL http://medrxiv.org/content/early/2021/11/29/2021.11.29.21266109.abstract
AB The rapid spread of the SARS-CoV-2 Variant of Concern (VOC) Gamma during late 2020 and early 2021 in Brazilian settings with high seroprevalence raised some concern about the potential role of reinfections in driving the epidemic. Very few cases of reinfection associated with the VOC Gamma, however, have been reported. Here we describe 25 cases of SARS-CoV-2 reinfection confirmed by real-time RT-PCR twice within months apart in Brazil. SARS-CoV-2 genomic analysis confirmed that individuals were primo-infected between March and December 2020 with distinct viral lineages, including B.1.1, B.1.1.28, B.1.1.33, B.1.195 and P.2, and then reinfected with the VOC Gamma between 3 to 12 months after primo-infection. The overall mean cycle threshold (Ct) value of the first (25.7) and second (24.5) episodes were roughly similar for the whole group and 14 individuals displayed mean Ct values < 25.0 at reinfection. Sera of 14 patients tested by plaque reduction neutralization test after reinfection displayed detectable neutralizing antibodies against Gamma and other SARS-CoV-2 variants (B.1.33, B.1.1.28 and Delta). All individuals have milder or no symptoms after reinfection and none required hospitalization. The present study demonstrates that the VOC Gamma was associated with reinfections during the second Brazilian epidemic wave in 2021 and raised concern about the potential infectiousness of reinfected subjects. Although individuals here analyzed failed to mount a long-term sterilizing immunity, they developed a high anti-Gamma neutralizing antibody response after reinfection that may provide some protection against severe disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding support from Department of Science and Technology (DECIT), Ministry of Health, CGLab/MoH (General Laboratories Coordination of Brazilian Ministry of Health), CVSLR/FIOCRUZ (Coordination of Health Surveillance and Reference Laboratories of Oswaldo Cruz Foundation), CNPq COVID-19 MCTI 402457/2020-0 and 403276/2020-9; INOVA Fiocruz VPPCB-005-FIO-20-2 and VPPCB-007-FIO-18-2-30; FAPERJ: E26/210.196/2020; FAPEAM (PCTI-EmergeSaude/AM call 005/2020 and Rede Genomica de Vigilancia em Saude - REGESAM). This study was also supported by a Grant-in Aid from the Japan Agency for Medical Research and Development (AMED) under Grant number JP20fk0108103.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Ethics Committee of the Amazonas State University (CAAE: 25430719.6.0000.5016) and by the Ethics Committee of the FIOCRUZ (CAAE: 68118417.6.0000.5248).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe consensus SARS-CoV-2 sequences generated in this work are available online at EpiCoV database in GISAID https://www.gisaid.org under the accession numbers: EPI_ISL_811148, EPI_ISL_811149, EPI_ISL_1034304 to 1034306, EPI_ISL_1114151, EPI_ISL_1534003, EPI_ISL_2017281 to 2017324, EPI_ISL_2017449, EPI_ISL_2187985, EPI_ISL_2187989, EPI_ISL_2187990, EPI_ISL_2188000, EPI_ISL_2196249 to 2196252, EPI_ISL_2196357, EPI_ISL_2196360 to 2196362, EPI_ISL_2227564, EPI_ISL_2497433 to 2497435, EPI_ISL_2497440, EPI_ISL_2497459, EPI_ISL_2497469, EPI_ISL_2617626, EPI_ISL_2617627, EPI_ISL_2645521, EPI_ISL_2921603 to 2921609, EPI_ISL_3061879, EPI_ISL_3061892, EPI_ISL_3061893, EPI_ISL_3061900 to 3061902, EPI_ISL_3087898, EPI_ISL_4563059 and EPI_ISL_4563061.